The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Open accessAbstract
Oncogenic TRK fusions induce cancer cell proliferation and engage critical cancer-related downstream signaling pathways. These TRK fusions occur rarely, but in a diverse spectrum of tumor histologies. LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. Preclinical models of LOXO-101 using TRK-fusion–bearing human-derived cancer cell lines demonstrate inhibition of the fusion oncoprotein and cellular proliferation in vitro, and tumor growth in vivo. The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an LMNA–NTRK1 gene fusion encoding a functional LMNA–TRKA fusion oncoprotein as determined by an in situ proximity ligation assay. In a phase I study of LOXO-101 (ClinicalTrials.gov no. NCT02122913), this patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen saturation, and plasma tumor markers. Significance: TRK fusions have been deemed putative oncogenic drivers, but their clinical significance remained unclear. A patient with a metastatic soft-tissue sarcoma with an LMNA–NTRK1 fusion had rapid and substantial tumor regression with a novel, highly selective TRK inhibitor, LOXO-101, providing the first clinical evidence of benefit from inhibiting TRK fusions. Cancer Discov; 5(10); 1049–57. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 1005
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Self-citationCeritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Kaplan, D. R., Martin-Zanca, D., & Parada, L. F. (1991) · Nature · doi:10.1038/350158a0 · Cited by 1,055
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Soft-Tissue Sarcomas in Adults
Clark, M. A., Fisher, C., Judson, I., & Thomas, J. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041866 · Cited by 907
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
Martin-Zanca, D., Hughes, S. H., & Barbacid, M. (1986) · Nature · doi:10.1038/319743a0 · Cited by 803
A comprehensive transcriptional portrait of human cancer cell lines
Klijn, C., Durinck, S., Stawiski, E. W., Haverty, P. M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3080 · Cited by 660
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
Wiesner, T., He, J., Yelensky, R., Esteve-Puig, R., Botton, T., Yeh, I., Lipson, D., Otto, G., Brennan, K., Murali, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4116 · Cited by 649
Self-citationTRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
Self-citationOncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
Self-citationThe transcriptional landscape and mutational profile of lung adenocarcinoma
Seo, J.-S., Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, J. K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J.-O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 584
Stephens, R. M., Loeb, D. M., Copeland, T. D., Pawson, T., Greene, L. A., & Kaplan, D. R. (1994) · Neuron · doi:10.1016/0896-6273(94)90223-2 · Cited by 541
Santoro, A., Tursz, T., Mouridsen, H., Verweij, J., Steward, W., Somers, R., Buesa, J., Casali, P., Spooner, D., & Rankin, E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1537 · Cited by 526
The integrated landscape of driver genomic alterations in glioblastoma
Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., Keir, S. T., Ji, A. X., Zoppoli, P., Niola, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2734 · Cited by 524
Trk receptor tyrosine kinases: A bridge between cancer and neural development
Nakagawara, A. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00530-4 · Cited by 495
Oncogenes in solid human tumours
Pulciani, S., Santos, E., Lauver, A. V., Long, L. K., Aaronson, S. A., & Barbacid, M. (1982) · Nature · doi:10.1038/300539a0 · Cited by 478
Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Lovly, C. M., Gupta, A., Lipson, D., Otto, G., Brennan, T., Chung, C. T., Borinstein, S. C., Ross, J. S., Stephens, P. J., Miller, V. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0377 · Cited by 455
Self-citationOncogenic FGFR3 gene fusions in bladder cancer
Williams, S. V., Hurst, C. D., & Knowles, M. A. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds486 · Cited by 390
Molecular Pathways: ROS1 Fusion Proteins in Cancer
Davies, K. D., & Doebele, R. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2851 · Cited by 373
Self-citationLorigan, P., Verweij, J., Papai, Z., Rodenhuis, S., Le Cesne, A., Leahy, M. G., Radford, J. A., Van Glabbeke, M. M., Kirkpatrick, A., Hogendoorn, P. C. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7717 · Cited by 256
Sleijfer, S., Ouali, M., van Glabbeke, M., Krarup-Hansen, A., Rodenhuis, S., Le Cesne, A., Hogendoorn, P. C. W., Verweij, J., & Blay, J.-Y. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.09.022 · Cited by 244
Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
Linch, M., Miah, A. B., Thway, K., Judson, I. R., & Benson, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.26 · Cited by 216
Keysar, S. B., Astling, D. P., Anderson, R. T., Vogler, B. W., Bowles, D. W., Morton, J. J., Paylor, J. J., Glogowska, M. J., Le, P. N., Eagles-Soukup, J. R., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.03.004 · Cited by 167
Self-citationResistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
Davies, K. D., Mahale, S., Astling, D. P., Aisner, D. L., Le, A. T., Hinz, T. K., Vaishnavi, A., Bunn, P. A., Heasley, L. E., Tan, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082236 · Cited by 128
Self-citationTaipale, M., Krykbaeva, I., Whitesell, L. J., Santagata, S., Zhang, J., Liu, Q., Gray, N. S., & Lindquist, S. L. (2013) · Nature Biotechnology · doi:10.1038/nbt.2620 · Cited by 128
Rutkowski, P. L., Dêbiec‐Rychter, M., Nowecki, Z., Michej, W., Symonides, M., Ptaszyński, K., & Ruka, W. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03774.x · Cited by 82
Nerve Growth Factor-Induced Migration of Endothelial Cells
Dollé, J.-P., Rezvan, A., Allen, F. D., Lazarovici, P., & Lelkes, P. I. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093252 · Cited by 80
Smith, M. A., Hall, R. D., Fisher, K. J., Haake, S. M., Khalil, F. K., Schabath, M. B., Vuaroqueaux, V., Fiebig, H., Altiok, S., Chen, Y. A., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005906 · Cited by 53
Cited by
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationRNA sequencing: the teenage years
Stark, R., Grzelak, M., & Hadfield, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0150-2 · Cited by 1,915
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Self-citationNTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Metadata
- Authors
- Doebele, R. C., Davis, L. E., Vaishnavi, A., Le, A. T., Estrada-Bernal, A., Keysar, S., Jimeno, A., Varella-Garcia, M., Aisner, D. L., Li, Y., Stephens, P. J., Morosini, D., Tuch, B. B., Fernandes, M., Nanda, N., & Low, J. A.
- Venue
- Cancer Discovery
- Published
- 2015-09-30
- Volume
- 5
- Issue
- 10
- Pages
- 1049-1057
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2180425334
- Cited by
- 388
- References
- 29
- FWCI
- 27.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.